title: Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
abstract: BACKGROUND
  CA125 is very helpful in treatment monitoring and detection of epithelial ovarian cancer (EOC) recurrence. However there is controversy as to its accuracy and optimal usage. What is the impact of the CA125 levels before primary surgery treatment to the survival of patients? This study aimed to detect any association of preoperative serum levels with prognosis and survival in EOC patients.
  
  
  METHODS
  Our cohort comprised EOC patients in Dr. Sardjito Hospital, Yogyakarta, Indonesia, who complied with follow up. To explore the effect of preoperative CA125 levels and other variables on survival Cox's regression models were applied.
  
  
  RESULTS
  A total of 90 cases of EOC who had surgery were available for follow up. The level of CA125 poroved to be a prognostic factor for overall survival of EOC patients, with an adjusted HR of 4.10 (p = 0.03). Adjuvant chemotherapy was another prognostic factor, 1 - 2 cycles having an adjusted HR of 0.17 (p = 0.04) and 3 - 8 cycles HR 0.39 (p = 0.06). Other factors such as age of patients adjusted HR 1.54 (p = 0.32), moderate differentiation (adjusted HR 1.61, p = 0.51) poor differentiation (adjusted HR 3.41, p = 0.15), and stage of disease (adjusted HR 1.98, p = 0.27) were statistically not significant. However, this might have been because the power of the study was low.
  
  
  CONCLUSIONS
  Preoperative level of CA125 is a prognostic factor for overall survival in EOC patients. The best cut-off for prognostic classification of CA125 serum level is 70 U/ml.
authors.affiliation: Obstetric and Gynecology Department, Faculty of Medicine, Universitas Gadjah Mada and Sardjito Central Hospital, Yogyakarta, Indonesia E-mail : herupradjatmo@gmail.com.
authors.forename: Heru
authors.initials: H
authors.lastname: Pradjatmo
authors.forename: Heru
authors.initials: H
authors.lastname: Pradjatmo
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000097:blood / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D002288:Adenocarcinoma, Mucinous / Q000097:blood / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018284:Cystadenocarcinoma, Serous / Q000097:blood / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D016889:Endometrial Neoplasms / Q000097:blood / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007214:Indonesia / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011300:Preoperative Care; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen